You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarprofen
Accession NumberDB00821  (APRD00849)
TypeSmall Molecule
GroupsApproved, Vet Approved, Withdrawn
DescriptionCarprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. Carprofen was previously used in human medicine for over 10 years (1985-1995). It was generally well tolerated, with the majority of adverse effects being mild, such as gastro-intestinal pain and nausea, similar to those recorded with aspirin and other non-steroidal anti-inflammatory drugs. It is no longer marketed for human usage, after being withdrawn on commercial grounds. [Wikipedia]
Structure
Thumb
Synonyms
(+-)-6-chloro-alpha-Methylcarbazole-2-acetic acid
(+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid
2-(6-Chloro-9H-carbazol-2-yl)-propionic acid
6-chloro-alpha-Methyl-9H-carbazole-2-acetic acid
Carprofen
Carprofène
Carprofeno
Carprofenum
External Identifiers
  • C 5720
  • C 8012
  • Ro 20-5720/000
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
lmadylRoche
lmafenRoche
RimadytRoche
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIFFL0D546HO
CAS number53716-49-7
WeightAverage: 273.714
Monoisotopic: 273.05565634
Chemical FormulaC15H12ClNO2
InChI KeyInChIKey=PUXBGTOOZJQSKH-UHFFFAOYSA-N
InChI
InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)
IUPAC Name
2-(6-chloro-9H-carbazol-2-yl)propanoic acid
SMILES
CC(C(O)=O)C1=CC2=C(C=C1)C1=C(N2)C=CC(Cl)=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassCarbazoles
Direct ParentCarbazoles
Alternative Parents
Substituents
  • Carbazole
  • Indole
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Pyrrole
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use as a pain reliever in the treatment of joint pain and post-surgical pain.
PharmacodynamicsCarprofen is a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid class that includes ibuprofen, naproxen, and ketoprofen. It is no longer used in the clinical setting, but is approved for use in dogs. Carprofen is non-narcotic and has characteristic analgesic and antipyretic activity approximately equipotent to indomethacin in animal models.
Mechanism of actionThe mechanism of action of carprofen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals. The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity. In an in vitro study using canine cell cultures, carprofen demonstrated selective inhibition of COX-2 versus COX-1.
Related Articles
AbsorptionRapidly and nearly completely absorbed (more than 90% bioavailable) when administered orally.
Volume of distributionNot Available
Protein bindingHigh (99%)
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeApproximately 8 hours (range 4.5–9.8 hours) in dogs.
ClearanceNot Available
ToxicitySymptoms of NSAID overdose include dizziness and nystagmus. Oral LD50 in mouse and rat is 282 mg/kg and 149 mg/kg, respectively.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Carprofen Action PathwayDrug actionSMP00694
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9742
Caco-2 permeable+0.5595
P-glycoprotein substrateNon-substrate0.7062
P-glycoprotein inhibitor INon-inhibitor0.985
P-glycoprotein inhibitor IINon-inhibitor0.9319
Renal organic cation transporterNon-inhibitor0.8485
CYP450 2C9 substrateNon-substrate0.7405
CYP450 2D6 substrateNon-substrate0.8318
CYP450 3A4 substrateNon-substrate0.6389
CYP450 1A2 substrateInhibitor0.6573
CYP450 2C9 inhibitorNon-inhibitor0.7193
CYP450 2D6 inhibitorNon-inhibitor0.9481
CYP450 2C19 inhibitorNon-inhibitor0.7037
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.794
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8521
BiodegradationNot ready biodegradable0.9874
Rat acute toxicity3.4155 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9725
hERG inhibition (predictor II)Non-inhibitor0.8697
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
Packagers
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point195-199Berger, L. and Corraz, A.J.; US. Patent 3,896,145; July 22,1975; assigned to Hoffmann- LaRoche, Inc.
water solubilityPractically insoluble at 25 °CNot Available
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00379 mg/mLALOGPS
logP4.09ALOGPS
logP3.88ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)4.42ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area53.09 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity74.16 m3·mol-1ChemAxon
Polarizability28.56 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Berger, L. and Corraz, A.J.; US. Patent 3,896,145; July 22,1975; assigned to Hoffmann-
LaRoche, Inc.

General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (24.5 KB)
Interactions
Drug Interactions
Drug
AbciximabCarprofen may increase the anticoagulant activities of Abciximab.
AcebutololCarprofen may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Carprofen is combined with Aceclofenac.
AcenocoumarolCarprofen may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Carprofen.
Alendronic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Alendronic acid.
AliskirenCarprofen may decrease the antihypertensive activities of Aliskiren.
AlprenololCarprofen may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Carprofen.
AmikacinCarprofen may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideCarprofen may decrease the antihypertensive activities of Amiloride.
AncrodCarprofen may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Carprofen is combined with Antipyrine.
Antithrombin III humanCarprofen may increase the anticoagulant activities of Antithrombin III human.
ApixabanCarprofen may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Carprofen is combined with Apremilast.
ArdeparinCarprofen may increase the anticoagulant activities of Ardeparin.
ArgatrobanCarprofen may increase the anticoagulant activities of Argatroban.
ArotinololCarprofen may decrease the antihypertensive activities of Arotinolol.
AtenololCarprofen may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Carprofen is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Carprofen.
BalsalazideCarprofen may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Carprofen.
BecaplerminCarprofen may increase the anticoagulant activities of Becaplermin.
BefunololCarprofen may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Carprofen.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Carprofen.
BenoxaprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Benoxaprofen.
BetaxololCarprofen may decrease the antihypertensive activities of Betaxolol.
BevantololCarprofen may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Carprofen.
BisoprololCarprofen may decrease the antihypertensive activities of Bisoprolol.
BivalirudinCarprofen may increase the anticoagulant activities of Bivalirudin.
BopindololCarprofen may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Carprofen is combined with Bromfenac.
BufuralolCarprofen may decrease the antihypertensive activities of Bufuralol.
BumetanideCarprofen may decrease the diuretic activities of Bumetanide.
BupranololCarprofen may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Carprofen.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Carprofen.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Carprofen.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Carprofen.
CarteololCarprofen may decrease the antihypertensive activities of Carteolol.
CarvedilolCarprofen may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Carprofen is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Carprofen.
CeliprololCarprofen may decrease the antihypertensive activities of Celiprolol.
CertoparinCarprofen may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Carprofen.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Carprofen.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Carprofen.
CholestyramineCholestyramine can cause a decrease in the absorption of Carprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Carprofen.
Citric AcidCarprofen may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Carprofen is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Carprofen is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Carprofen.
ColesevelamColesevelam can cause a decrease in the absorption of Carprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Carprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineCarprofen may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Carprofen is combined with D-Limonene.
Dabigatran etexilateCarprofen may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinCarprofen may increase the anticoagulant activities of Dalteparin.
DanaparoidCarprofen may increase the anticoagulant activities of Danaparoid.
DaunorubicinCarprofen may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Carprofen is combined with Deferasirox.
DesirudinCarprofen may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Carprofen is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Carprofen.
DextranCarprofen may increase the anticoagulant activities of Dextran.
Dextran 40Carprofen may increase the anticoagulant activities of Dextran 40.
Dextran 70Carprofen may increase the anticoagulant activities of Dextran 70.
Dextran 75Carprofen may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Carprofen.
DicoumarolCarprofen may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Carprofen is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Carprofen.
DihydrostreptomycinCarprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Carprofen.
DoxorubicinCarprofen may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneCarprofen may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Carprofen is combined with Droxicam.
Edetic AcidCarprofen may increase the anticoagulant activities of Edetic Acid.
EdoxabanCarprofen may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Carprofen.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Carprofen.
EnoxaparinCarprofen may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Carprofen is combined with Epirizole.
EpirubicinCarprofen may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneCarprofen may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Carprofen.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carprofen.
EsmololCarprofen may decrease the antihypertensive activities of Esmolol.
Etacrynic acidCarprofen may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Carprofen.
Ethyl biscoumacetateCarprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Carprofen.
EtofenamateThe risk or severity of adverse effects can be increased when Carprofen is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Carprofen is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Carprofen is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Carprofen is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Carprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Carprofen.
FlunixinThe risk or severity of adverse effects can be increased when Carprofen is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Carprofen.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Carprofen.
Fondaparinux sodiumCarprofen may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Carprofen.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Carprofen.
FramycetinCarprofen may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideCarprofen may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Carprofen.
GentamicinCarprofen may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Carprofen is combined with Haloperidol.
HeparinCarprofen may increase the anticoagulant activities of Heparin.
HirulogCarprofen may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Carprofen is combined with HMPL-004.
HydralazineCarprofen may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Carprofen.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Carprofen.
Hygromycin BCarprofen may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Carprofen is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Carprofen is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Carprofen is combined with Icatibant.
IdarubicinCarprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Carprofen.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Carprofen.
IndenololCarprofen may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Carprofen.
IndoprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Carprofen.
IsoxicamThe risk or severity of adverse effects can be increased when Carprofen is combined with Isoxicam.
KanamycinCarprofen may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Carprofen.
LabetalolCarprofen may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Carprofen is combined with Leflunomide.
LepirudinCarprofen may increase the anticoagulant activities of Lepirudin.
LevobunololCarprofen may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Carprofen.
LithiumThe serum concentration of Lithium can be increased when it is combined with Carprofen.
LornoxicamThe risk or severity of adverse effects can be increased when Carprofen is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Carprofen.
LoxoprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Carprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Carprofen is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Carprofen is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Carprofen.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Carprofen.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Carprofen.
MesalazineCarprofen may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Carprofen.
MetamizoleThe risk or severity of adverse effects can be increased when Carprofen is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Carprofen.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Carprofen.
MetipranololCarprofen may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Carprofen.
MetoprololCarprofen may decrease the antihypertensive activities of Metoprolol.
MetrizamideCarprofen may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Carprofen.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Carprofen.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Carprofen.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Carprofen.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Carprofen.
NadololCarprofen may decrease the antihypertensive activities of Nadolol.
NadroparinCarprofen may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Carprofen.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Carprofen.
NCX 4016The risk or severity of adverse effects can be increased when Carprofen is combined with NCX 4016.
NeomycinCarprofen may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Carprofen is combined with Nepafenac.
NetilmicinCarprofen may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Carprofen is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Carprofen is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carprofen.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Carprofen.
OlsalazineCarprofen may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Carprofen.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Carprofen is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Carprofen.
OrgoteinThe risk or severity of adverse effects can be increased when Carprofen is combined with Orgotein.
OtamixabanCarprofen may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Carprofen is combined with Oxaprozin.
OxprenololCarprofen may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Carprofen is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Carprofen is combined with Parecoxib.
ParomomycinCarprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololCarprofen may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateCarprofen may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Carprofen.
PhenindioneCarprofen may increase the anticoagulant activities of Phenindione.
PhenprocoumonCarprofen may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Carprofen.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carprofen.
PindololCarprofen may decrease the antihypertensive activities of Pindolol.
PiretanideCarprofen may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Carprofen is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Carprofen.
PlicamycinCarprofen may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Carprofen.
PorfimerCarprofen may increase the photosensitizing activities of Porfimer.
PractololCarprofen may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Carprofen.
ProbenecidThe serum concentration of Carprofen can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Carprofen is combined with Propacetamol.
PropranololCarprofen may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Carprofen.
Protein CCarprofen may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeCarprofen may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Carprofen is combined with PTC299.
PuromycinCarprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Carprofen.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Carprofen.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Carprofen.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Carprofen.
ResveratrolThe risk or severity of adverse effects can be increased when Carprofen is combined with Resveratrol.
ReviparinCarprofen may increase the anticoagulant activities of Reviparin.
RibostamycinCarprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Carprofen is combined with Risedronate.
RivaroxabanCarprofen may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Carprofen.
SalicylamideThe risk or severity of adverse effects can be increased when Carprofen is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Carprofen is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Carprofen.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Carprofen.
SeratrodastThe risk or severity of adverse effects can be increased when Carprofen is combined with Seratrodast.
SotalolCarprofen may decrease the antihypertensive activities of Sotalol.
SpectinomycinCarprofen may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Carprofen.
SpironolactoneCarprofen may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Carprofen is combined with SRT501.
StreptomycinCarprofen may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinCarprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineCarprofen may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Carprofen.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Carprofen.
SulodexideCarprofen may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Suprofen.
TacrolimusCarprofen may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Carprofen.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Carprofen.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Carprofen is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carprofen.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Carprofen.
TenofovirThe risk or severity of adverse effects can be increased when Carprofen is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Carprofen.
TepoxalinThe risk or severity of adverse effects can be increased when Carprofen is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Carprofen is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Tiaprofenic acid.
TiludronateThe risk or severity of adverse effects can be increased when Carprofen is combined with Tiludronate.
TimololCarprofen may decrease the antihypertensive activities of Timolol.
TobramycinCarprofen may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Carprofen is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Carprofen.
TorasemideCarprofen may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Carprofen.
TranilastThe risk or severity of adverse effects can be increased when Carprofen is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Carprofen.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Carprofen.
TriamtereneCarprofen may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Carprofen.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Carprofen is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Carprofen.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Carprofen.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Carprofen.
VerteporfinCarprofen may increase the photosensitizing activities of Verteporfin.
WarfarinCarprofen may increase the anticoagulant activities of Warfarin.
XimelagatranCarprofen may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Carprofen.
Zoledronic acidThe risk or severity of adverse effects can be increased when Carprofen is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Carprofen is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Kay-Mugford P, Benn SJ, LaMarre J, Conlon P: In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res. 2000 Jul;61(7):802-10. [PubMed:10895904 ]
  2. Brideau C, Van Staden C, Chan CC: In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res. 2001 Nov;62(11):1755-60. [PubMed:11703020 ]
  3. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222 ]
  4. Beretta C, Garavaglia G, Cavalli M: COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6. [PubMed:15939622 ]
  5. Narlawar R, Perez Revuelta BI, Haass C, Steiner H, Schmidt B, Baumann K: Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem. 2006 Dec 28;49(26):7588-91. [PubMed:17181139 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Beretta C, Garavaglia G, Cavalli M: COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6. [PubMed:15939622 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23